mirikizumab + tirzepatide

**Mirikizumab + tirzepatide** is a combination therapy being investigated for treating inflammatory bowel diseases (ulcerative colitis and Crohn's disease) in patients who also have obesity or are overweight.\n\nMirikizumab is a monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), inhibiting its inflammatory effects in inflammatory bowel diseases. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood glucose, digestion, and appetite.\n\nThe combination aims to simultaneously address both the inflammatory aspects of bowel disease and metabolic issues related to obesity.

Brand names

OmvohMounjaroZepbound

Other names

Mirikizumab and Tirzepatide combinationMirikizumab concomitantly administered with Tirzepatide